Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients

被引：13
作者：
Liu, Yachao [1 ]
Wang, Guanyun [1 ,2 ]
Yu, Hongkai [3 ]
Wu, Yue [4 ]
Lin, Mu [4 ]
Gao, Jiangping [3 ]
Xu, Baixuan [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Nucl Med, Beijing 100853, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Sch Chinese PLA, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Urol Surg, Beijing, Peoples R China
[4] Siemens Healthineers Ltd, Diagnost Imaging, MR Collaborat, Shanghai, Peoples R China
来源：
NUCLEAR MEDICINE COMMUNICATIONS | 2020年 / 41卷 / 12期
基金：
中国国家自然科学基金;
关键词：
clear cell renal cell carcinoma; prostate-specific membrane antigen; local recurrence; metastases; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; MEMBRANE ANTIGEN; FDG-PET/CT; UTILITY;
D O I：
10.1097/MNM.0000000000001285
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Objectives This study aimed to compare the diagnostic performance of F-18-DCFPyL and 2-deoxy-2-[F-18]fluoro-D-glucose (F-18-FDG PET/computed tomography in the restaging of clear cell renal cell carcinoma after nephrectomy. Methods In this retrospective study, a total of 15 patients with suspected local recurrence of clear cell renal cell carcinoma or metastasis after surgery underwent both F-18-DCFPyL and F-18-FDG PET/computed tomography. A systematic comparison of the maximum standardized uptake value and the target to background ratio was carried out between the lesions detected by the two tracers. Results A total of 42 lesions were detected either by F-18-DCFPyL PET/computed tomography or by F-18-FDG PET/computed tomography. F-18-DCFPyL PET/computed tomography, but not F-18-FDG PET/computed tomography, accurately distinguished the two local recurrence from four postoperative changes. The remaining 36 lesions were soft tissue (14) and bone lesions (22); all 36 lesions were detected by F-18-DCFPyL PET/computed tomography while only 10 (10/14) soft tissue lesions and 12 (12/22) bone lesions were detected by F-18-FDG PET/computed tomography. The higher detection rate of soft tissue lesions using F-18-DCFPyL PET/computed tomography was not statistically significant (P = 0.125); however, F-18-DCFPyL PET/computed tomography was statistically better (P = 0.002) at detecting bone lesions. The average maximum standardized uptake value and target to background ratio of F-18-DCFPyL were significantly higher than that of F-18-FDG for soft tissue lesions (maximum standardized uptake value P = 0.005; target to background ratio P = 0.028) and bone lesions (maximum standardized uptake value P = 0.001; target to background ratio P = 0.001). Conclusions Our preliminary results indicated that F-18-DCFPyL PET/computed tomography is superior to F-18-FDG PET/computed tomography for the detection of local recurrence at both the surgical site and in bone metastasis while the tracers are comparable in the detection of soft tissue metastases.
引用
收藏
页码：1299 / 1305
页数：7
相关论文
共 25 条
[1]   A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC) [J].
Ahn, Thomas ;
Roberts, Matthew J. ;
Abduljabar, Aous ;
Joshi, Andre ;
Perera, Marlon ;
Rhee, Handoo ;
Wood, Simon ;
Vela, Ian .
MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (05) :799-807
[2]   Bone Metastasis from Renal Cell Carcinoma [J].
Chen, Szu-Chia ;
Kuo, Po-Lin .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06)
[3]   2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer [J].
Chen, Ying ;
Pullambhatla, Mrudula ;
Foss, Catherine A. ;
Byun, Youngjoo ;
Nimmagadda, Sridhar ;
Senthamizhchelvan, Srinivasan ;
Sgouros, George ;
Mease, Ronnie C. ;
Pomper, Martin G. .
CLINICAL CANCER RESEARCH, 2011, 17 (24) :7645-7653
[4]   Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents [J].
Czarniecki, Marcin ;
Mena, Esther ;
Lindenberg, Liza ;
Cacko, Marek ;
Harmon, Stephanie ;
Radtke, Jan Philipp ;
Giesel, Frederick ;
Turkbey, Baris ;
Choyke, Peter L. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (05) :831-843
[5]   68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma [J].
Demirci, Emre ;
Ocak, Meltem ;
Kabasakal, Levent ;
Decristoforo, Clemens ;
Talat, Zubeyir ;
Halac, Metin ;
Kanmaz, Bedii .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (07) :1461-1462
[6]   Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer [J].
Dietlein, Markus ;
Kobe, Carsten ;
Kuhnert, Georg ;
Stockter, Simone ;
Fischer, Thomas ;
Schomaecker, Klaus ;
Schmidt, Matthias ;
Dietlein, Felix ;
Zlatopolskiy, Boris D. ;
Krapf, Philipp ;
Richarz, Raphael ;
Neubauer, Stephan ;
Drzezga, Alexander ;
Neumaier, Bernd .
MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (04) :575-584
[7]   Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Escudier, B. ;
Porta, C. ;
Schmidinger, M. ;
Rioux-Leclercq, N. ;
Bex, A. ;
Khoo, V. ;
Gruenvald, V. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2016, 27 :v58-v68
[8]   FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls [J].
Garg, Gunjan ;
Benchekroun, Mohammed Taoudi ;
Abraham, Tony .
SEMINARS IN NUCLEAR MEDICINE, 2017, 47 (06) :579-594
[9]   Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design [J].
Gerety, E. L. ;
Lawrence, E. M. ;
Wason, J. ;
Yan, H. ;
Hilborne, S. ;
Buscombe, J. ;
Cheow, H. K. ;
Shaw, A. S. ;
Bird, N. ;
Fife, K. ;
Heard, S. ;
Lomas, D. J. ;
Matakidou, A. ;
Soloviev, D. ;
Eisen, T. ;
Gallagher, F. A. .
ANNALS OF ONCOLOGY, 2015, 26 (10) :2113-2118
[10]   Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma [J].
Karivedu, Vidhya ;
Jain, Amit L. ;
Eluvathingal, Thomas J. ;
Sidana, Abhinav .
CURRENT UROLOGY REPORTS, 2019, 20 (10)
123